Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,617
Employees2,617
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,617
Employees2,617

INCY Key Statistics

Market cap
19.66B
Market cap19.66B
Price-Earnings ratio
16.79
Price-Earnings ratio16.79
Dividend yield
Dividend yield
Average volume
1.71M
Average volume1.71M
High today
$101.21
High today$101.21
Low today
$99.28
Low today$99.28
Open price
$100.77
Open price$100.77
Volume
1.99M
Volume1.99M
52 Week high
$112.29
52 Week high$112.29
52 Week low
$53.56
52 Week low$53.56

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $100.00. The company's market cap stands at 19.66B, with a P/E ratio of 16.79.

On 2026-01-31, Incyte(INCY) stock moved within a range of $99.28 to $101.21. With shares now at $100.00, the stock is trading +0.7% above its intraday low and -1.2% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 1.99M, versus its average volume of 1.71M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

INCY News

TipRanks 21h
Incyte announces CHMP opinion recommending approval of Zynyz combination

Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued an opinion recommending the approval...

Simply Wall St 7d
Assessing Incyte Valuation After Wells Fargo Rating Cut And Cooler Near Term Catalysts

Advertisement What triggered the latest move in Incyte (INCY)? Wells Fargo’s decision to cut its rating on Incyte (INCY) from Overweight to Equal Weight, alon...

Assessing Incyte Valuation After Wells Fargo Rating Cut And Cooler Near Term Catalysts

Analyst ratings

50%

of 28 ratings
Buy
39.3%
Hold
50%
Sell
10.7%

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.